Content
@
0 reply
0 recast
0 reaction
christin
@christin
I've helped dozens of pharmaceutical companies educate healthcare providers about diseases, the latest treatment options, and the harrowing journey patients go through. You would think these are topics that medical schools cover, but healthcare is evolving so quickly that continual medical education is often provided by drug companies. Education is especially vital for rare diseases. They are not top-of-mind for healthcare professionals because they're by definition uncommon. I remember working on marketing a drug for idiopathic pulmonary fibrosis, a rare lung disease. Since treatments available only slowed down progression and are not curative, doctors often opted to "watch and wait." This robbed patients of years of their lives in a silent way. Both my company and the competitor spent millions on medical education, bc the true competitor wasn't between the companies, it was against the inertia of "watch and wait." Yet inertia can be conquered: by educating customers, we empowered them to take action.
18 replies
8 recasts
41 reactions
λλΆλ§π»ββοΈ
@dubumother
I'm truly moved by what you shared. I completely agree with you about the importance of raising awareness and improving treatments for rare diseases in such a rapidly changing healthcare landscape. I recently came across a YouTube channel run by a young woman in her late twenties who was diagnosed with ALS. In her latest video, she shared how she's now reliant on a wheelchair and needs her mother's help with basic tasks like eating and bathing. Despite these challenges, she holds on to hope because of the possibility of new treatments. Seeing her situation, I found myself, like her family and friends, eagerly searching for any updates on new drugs. Your work in overcoming the inertia of "watch and wait" and providing patients with better choices is truly inspiring and admirable.
0 reply
0 recast
0 reaction
